Hepatitis C virus genotype 3: a genotype that is not ‘easy-to-treat’

References

• Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013;57(4):1333-42
   PubMed Web of Science ®Google Scholar
• Mühlberger N, Schwarzer R, Lettmeier B, et al. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health 2009;9(1):34
   PubMedGoogle Scholar
• Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest 2009;119(7):1745-54
   PubMed Web of Science ®Google Scholar
• Kanwal F, Hoang T, Kramer JR, et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology 2011;140(4):1182-8
   PubMed Web of Science ®Google Scholar
• Freeman AJ, Dore GJ, Law MG, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001;34(4):809-16
   PubMed Web of Science ®Google Scholar
• Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997;349(9055):825-32
   PubMed Web of Science ®Google Scholar
• Hu KQ, Tong MJ. The long term outcomes of patients with compensated hepatitis C virus–related cirrhosis and history of parenteral exposure in the united states. Hepatology 1999;29(4):1311-16
   PubMed Web of Science ®Google Scholar
• Fattovich G, Giustina G, Degos F, et al. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. J Hepatol 1997;27(1):201-5
   PubMed Web of Science ®Google Scholar
• Ferenci P, Fried M, Labrecque D, et al. World gastroenterology organisation global guideline. Hepatocellular carcinoma (HCC): a global perspective. J Gastrointest Liver Dis 2010;19(3):311-17
   PubMed Web of Science ®Google Scholar
• Bruno S, Silini E, Crosignani A, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology 1997;25(3):754-8
   PubMed Web of Science ®Google Scholar
• Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 2006;3(2):47-52
   PubMedGoogle Scholar
• Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006;45(4):529-38
   PubMed Web of Science ®Google Scholar
• Smith DB, Bukh J, Kuiken C, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 2014;59(1):318-27
   PubMed Web of Science ®Google Scholar
• Cornberg M, Razavi HA, Alberti A, et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int 2011;31:30-60
   PubMed Web of Science ®Google Scholar
• Sievert W, Altraif I, Razavi HA, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int 2011;31:61-80
   PubMed Web of Science ®Google Scholar
• Antaki N, Craxi A, Kamal S, et al. The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Liver Int 2010;30(3):342-55
   PubMed Web of Science ®Google Scholar
• Chao D, Abe K, Nguyen M. Systematic review: epidemiology of hepatitis C genotype 6 and its management. Aliment Pharmacol Ther 2011;34(3):286-96
   PubMed Web of Science ®Google Scholar
• Esteban JI, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 2008;48(1):148-62
   PubMed Web of Science ®Google Scholar
• Kanwal F, Kramer JR, Ilyas J, et al. HCV Genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. veterans with HCV. Hepatology 2014;60(1):98-105
   PubMed Web of Science ®Google Scholar
• McCombs J, Matsuda T, Tonnu-Mihara I, et al. The risk of long-term morbidity and mortality in patients with chronic hepatitis C: results from an analysis of data from a department of veterans affairs clinical registry. JAMA Internal Med 2013;174(2):204-121
   Web of Science ®Google Scholar
• European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2014;60(2):392-420
   PubMed Web of Science ®Google Scholar
• Martinot Peignoux M, Stern C, Maylin S, et al. Twelve weeks posttreatment follow up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology 2010;51(4):1122-6
   PubMed Web of Science ®Google Scholar
• Ramachandran P, Fraser A, Agarwal K, et al. UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients. Aliment Pharmacol Ther 2012;35(6):647-62
   PubMed Web of Science ®Google Scholar
• Khattab MA, Ferenci P, Hadziyannis SJ, et al. Management of hepatitis C virus genotype 4: recommendations of an international expert panel. J Hepatol 2011;54(6):1250-62
   PubMed Web of Science ®Google Scholar
• Lu L, Li C, Yuan J, et al. Full-length genome sequences of five hepatitis C virus isolates representing subtypes 3g, 3h, 3i and 3k, and a unique genotype 3 variant. J Gen Virol 2013;94(Pt 3):543-8
   PubMed Web of Science ®Google Scholar
• Shoeb D, Dearden J, Weatherall A, et al. Extended duration therapy with pegylated interferon and ribavirin for patients with genotype 3 hepatitis C and advanced fibrosis: final results from the STEPS trial. J Hepatol 2014;60(4):699-705
   PubMed Web of Science ®Google Scholar
• Lemon SM. Induction and evasion of innate antiviral responses by hepatitis C virus. J Biol Chem 2010;285(30):22741-7
   PubMed Web of Science ®Google Scholar
• Andriulli A, Mangia A, Iacobellis A, et al. Meta analysis: The outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. Aliment Pharmacol Ther 2008;28(4):397-404
   PubMed Web of Science ®Google Scholar
• Gatselis NK, Zachou K, Saitis A, et al. Individualization of chronic hepatitis C treatment according to the host characteristics. World J Gastroenterol 2014;20(11):2839-53
   PubMed Web of Science ®Google Scholar
• Ampuero J, Romero-Gómez M, Reddy KR. Review article: HCV genotype 3–the new treatment challenge. Aliment Pharmacol Ther 2014;39(7):686-98
   PubMed Web of Science ®Google Scholar
• Westin J, Nordlinder H, Lagging M, et al. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J Hepatol 2002;37(6):837-42
   PubMed Web of Science ®Google Scholar
• Mihm S, Fayyazi A, Hartmann H, Ramadori G. Analysis of histopathological manifestations of chronic hepatitis C virus infection with respect to virus genotype. Hepatology 1997;25(3):735-9
   PubMed Web of Science ®Google Scholar
• Poynard T, Ratziu V, McHutchison J, et al. Effect of treatment with peginterferon or interferon alfa 2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003;38(1):75-85
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Hultcrantz R, Bourliere M, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004;40(6):993-9
   PubMed Web of Science ®Google Scholar
• Rubbia-Brandt L, Quadri R, Abid K, et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 2000;33(1):106-15
   PubMed Web of Science ®Google Scholar
• Adinolfi LE, Gambardella M, Andreana A, et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001;33(6):1358-64
   PubMed Web of Science ®Google Scholar
• Kumar D, Farrell GC, Fung C, George J. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after sustained therapeutic response. Hepatology 2002;36(5):1266-72
   PubMed Web of Science ®Google Scholar
• Aghemo A, Rumi MG, Monico S, et al. The pattern of pegylated interferon-alpha2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype. Antivir Ther 2009;14(4):577-84
   PubMed Web of Science ®Google Scholar
• Powis J, Peltekian K, Lee S, et al. Exploring differences in response to treatment with peginterferon alpha 2a (40kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3. J Viral Hepatit 2008;15(1):52-7
   PubMed Web of Science ®Google Scholar
• Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013;368(20):1867-77
   PubMed Web of Science ®Google Scholar
• Beltrán-Sánchez H, Harhay MO, Harhay MM, McElligott S. Prevalence and Trends of Metabolic Syndrome in the Adult U.S. Population (Paris), 1999–2010. J Am Coll Cardiol 2013;62(8):697-703
   PubMed Web of Science ®Google Scholar
• Poustchi H, Negro F, Hui J, et al. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J Hepatol 2008;48(1):28-34
   PubMed Web of Science ®Google Scholar
• D’Souza R, Sabin C, Foster G. Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J Gastroenterol 2005;100(7):1509-15
   PubMed Web of Science ®Google Scholar
• Dai CY, Huang JF, Hsieh MY, et al. Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. J Hepatol 2009;50(4):712-18
   PubMed Web of Science ®Google Scholar
• Eslam M, Aparcero R, Kawaguchi T, et al. Meta-analysis: Insulin resistance and sustained virological response in hepatitis C. Aliment Pharmacol Ther 2011;34(3):297-305
   PubMed Web of Science ®Google Scholar
• Fattovich G, Covolo L, Bibert S, et al. IL28B polymorphisms, IP10 and viral load predict virological response to therapy in chronic hepatitis C. Aliment Pharmacol Ther 2011;33(10):1162-72
   PubMed Web of Science ®Google Scholar
• Alsiö Å, Rembeck K, Askarieh G, et al. Impact of obesity on the bioavailability of peginterferon-α2a and ribavirin and treatment outcome for chronic hepatitis c genotype 2 or 3. PLoS One 2012;7(5):e37521
   PubMed Web of Science ®Google Scholar
• Hegde V, Dhurandhar NV. Microbes and obesity—interrelationship between infection, adipose tissue and the immune system. Clin Microbiol Infect 2013;19(4):314-20
   PubMed Web of Science ®Google Scholar
• Papakonstantinou E, Lambadiari V, Dimitriadis G, Zampelas A. Metabolic syndrome and cardiometabolic risk factors. Curr Vasc Pharmacol 2013;11(6):858-79
   PubMed Web of Science ®Google Scholar
• Schlecker C, Ultsch A, Geisslinger G, Lötsch J. The pharmacogenetic background of hepatitis C treatment. Mutat Res 2012;751(1):36-48
   Web of Science ®Google Scholar
• Fellay J, Thompson AJ, Ge D, et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 2010;464(7287):405-8
   PubMed Web of Science ®Google Scholar
• Ochi H, Maekawa T, Abe H, et al. ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy—a genome-wide study of Japanese HCV virus patients. Gastroenterology 2010;139(4):1190-7
   PubMed Web of Science ®Google Scholar
• Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461(7262):399-401
   PubMed Web of Science ®Google Scholar
• Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy. Nat Genet 2009;41(10):1100-4
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41(10):1105-9
   PubMed Web of Science ®Google Scholar
• Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010;138(4):1338-45
   PubMed Web of Science ®Google Scholar
• Sarrazin C, Susser S, Doehring A, et al. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol 2011;54(3):415-21
   PubMed Web of Science ®Google Scholar
• Schreiber J, Moreno C, Garcia BG, et al. Meta-analysis: The impact of IL28B polymorphisms on rapid and sustained virological response in HCV2 and 3 patients. Aliment Pharmacol Ther 2012;36(4):353-62
   PubMed Web of Science ®Google Scholar
• Rembeck K, Waldenström J, Hellstrand K, et al. Variants of the inosine triphosphate pyrophosphatase gene are associated with reduced relapse risk following treatment for HCV genotype 2/3. Hepatology 2014;59(6):2131-9
   PubMed Web of Science ®Google Scholar
• Misra A, Khurana L. The metabolic syndrome in South Asians: epidemiology, determinants, and prevention. Metab Syndr Relat Disord 2009;7(6):497-514
   PubMed Web of Science ®Google Scholar
• Shoeb D, Rowe IA, Freshwater D, et al. Response to antiviral therapy in patients with genotype 3 chronic hepatitis C: fibrosis but not race encourages relapse. Eur J Gastroenterol Hepatol 2011;23(9):747-53
   PubMed Web of Science ®Google Scholar
• Li S, Hu P, Zhang QQ, et al. Single nucleotide polymorphisms of the IL28B and sustained virologic response of patients with chronic hepatitis C to PEG-interferon/ribavirin therapy: a meta-analysis. Hepat Mon 2011;11:3
   Web of Science ®Google Scholar
• Fried MW, Hadziyannis SJ, Shiffman ML, et al. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. J Hepatol 2011;55(1):69-75
   PubMed Web of Science ®Google Scholar
• Shiffman ML, Suter F, Bacon BR, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007;357(2):124-34
   PubMed Web of Science ®Google Scholar
• Diago M, Shiffman ML, Bronowicki JP, et al. Identifying hepatitis C virus genotype 2/3 patients who can receive a 16 week abbreviated course of peginterferon alfa2a (40KD) plus ribavirin. Hepatology 2010;51(6):1897-903
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014;370(21):1993-2001
   PubMed Web of Science ®Google Scholar
• Hernandez MD, Sherman KE. HIV/HCV coinfection natural history and disease progression, a review of the most recent literature. Curr Opin HIV AIDS 2011;6(6):478-82
   PubMed Web of Science ®Google Scholar
• Iorio A, Marchesini E, Awad T, Gluud LL. Antiviral treatment for chronic hepatitis C in patients with human immunodeficiency virus. Cochrane Database Syst Rev 2010;1
   Google Scholar
• López-Cortés LF, Ruiz-Valderas R, Jimenez-Jimenez L, et al. Influence of IL28B polymorphisms on response to a lower-than-standard dose peg-IFN-α 2a for genotype 3 chronic hepatitis C in HIV-coinfected patients. PLoS One 2012;7(1):e28115
   PubMed Web of Science ®Google Scholar
• Pineda JA, Caruz A, Rivero A, et al. Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis 2010;51(7):788-95
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Naggie S, Lalezari J, et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA 2014;312(4):353-61
   PubMed Web of Science ®Google Scholar
• Peveling-Oberhag J, Zeuzem S, Hofmann WP. Antiviral therapy of chronic hepatitis C in patients with advanced liver disease and after liver transplantation. Med Microbiol Immunol 2010;199(1):1-10
   PubMed Web of Science ®Google Scholar
• Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008;49(2):274-87
   PubMed Web of Science ®Google Scholar
• Ueda Y, Kaido T, Ogura Y, et al. Pretransplant serum hepatitis C virus RNA levels predict response to antiviral treatment after living donor liver transplantation. PLoS One 2013;8(3):e58380
   PubMed Web of Science ®Google Scholar
• Pol S, Vallet Pichard A, Corouge M. Treatment of hepatitis C virus genotype 3 infection. Liver Int 2014;34(s1):18-23
   PubMedGoogle Scholar
• Schinazi R, Halfon P, Marcellin P, Asselah T. HCV direct acting antiviral agents: the best interferon-free combinations. Liver Int 2014;34(s1):69-78
   Google Scholar
• Clark VC, Peter JA, Nelson DR. New therapeutic strategies in HCV: second generation protease inhibitors. Liver Int 2013;33(s1):80-4
   PubMedGoogle Scholar
• Petry A, Brainard DM, Van Dyck K, et al. Safety and antiviral activity of MK-5172, a novel HCV NS3/4a protease inhibitor with potent activity against known resistance mutants, in genotype 1 and 3 HCV-infected patients. In: 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). 2010
   Google Scholar
• Summa V, Ludmerer SW, McCauley JA, et al. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother 2012;56(8):4161-7
   PubMed Web of Science ®Google Scholar
• Dore G, Lawitz E, H’ezode C, et al. Daclatasvir combined with peginterferon alfa-2a and ribavirin for 12 or 16 weeks in patients with HCV genotype 2 or 3 infection: combined GT2/3 study. J Hepatol 2013;58:S570-1
   Web of Science ®Google Scholar
• Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014;370(3):211-21
   PubMed Web of Science ®Google Scholar
• Moghaddam A, Melum E, Reinton N, et al. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Hepatology 2011;53(3):746-54
   PubMed Web of Science ®Google Scholar
• Scherzer TM, Hofer H, Staettermayer AF, et al. Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin. J Hepatol 2011;54(5):866-71
   PubMed Web of Science ®Google Scholar
• Amanzada A, Goralczyk A, Moriconi F, et al. Ultra-rapid virologic response, young age, low γ-GT/ALT-ratio, and absence of steatosis identify a subgroup of HCV genotype 3 patients who achieve SVR with IFN-α2a monotherapy. Dig Dis Sci 2011;56(11):3296-304
   PubMed Web of Science ®Google Scholar
• Stenkvist J, Sönnerborg A, Weiland O. HCV RNA decline in chronic HCV genotype 2 and 3 during standard of care treatment according to IL28B polymorphism. J Viral Hepat 2013;20(3):193-9
   PubMed Web of Science ®Google Scholar